Somatostatin analogues for the prevention of pancreatic fistula after open pancreatoduodenectomy: A nationwide analysis

Dutch Pancreatic Cancer Group, Boukje T Bootsma*, Victor D Plat, Tim van de Brug, Daitlin E Huisman, M Botti, Peter B van den Boezem, Bert A Bonsing, Koop Bosscha, Cornelis H C Dejong, Bas Groot-Koerkamp, Jeroen Hagendoorn, Erwin van der Harst, Ignace H de Hingh, Vincent E de Meijer, Misha D Luyer, Vincent B Nieuwenhuijs, Bobby K Pranger, Hjalmar C van Santvoort, Jan H WijsmanBarbara M Zonderhuis, Geert Kazemier, Marc G Besselink, Freek Daams

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)
41 Downloads (Pure)


BACKGROUND: Somatostatin analogues (SA) are currently used to prevent postoperative pancreatic fistula (POPF) development. However, its use is controversial. This study investigated the effect of different SA protocols on the incidence of POPF after pancreatoduodenectomy in a nationwide population.

METHODS: All patients undergoing elective open pancreatoduodenectomy were included from the Dutch Pancreatic Cancer Audit (2014-2017). Patients were divided into six groups: no SA, octreotide, lanreotide, pasireotide, octreotide only in high-risk (HR) patients and lanreotide only in HR patients. Primary endpoint was POPF grade B/C. The updated alternative Fistula Risk Score was used to compare POPF rates across various risk scenarios.

RESULTS: 1992 patients were included. Overall POPF rate was 13.1%. Lanreotide (10.0%), octreotide-HR (9.4%) and no protocol (12.7%) POPF rates were lower compared to the other protocols (varying from 15.1 to 19.1%, p = 0.001) in crude analysis. Sub-analysis in patients with HR of POPF showed a significantly lower rate of POPF when treated with lanreotide (10.0%) compared to no protocol, octreotide and pasireotide protocol (21.6-26.9%, p = 0.006). Octreotide-HR and lanreotide-HR protocol POPF rates were comparable to lanreotide protocol, however not significantly different from the other protocols. Multivariable regression analysis demonstrated lanreotide protocol to be positively associated with a low odds-ratio (OR) for POPF (OR 0.387, 95% CI 0.180-0.834, p = 0.015). In-hospital mortality rates were not affected.

CONCLUSION: Use of lanreotide in all patients undergoing pancreatoduodenectomy has a potential protective effect on POPF development. Protocols for HR patients only might be favorable too. However, future studies are warranted to confirm these findings.

Original languageEnglish
Pages (from-to)421-426
Number of pages5
Issue number3
Early online date10-Mar-2022
Publication statusPublished - Apr-2022

Cite this